title: Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
abstract: Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM.
authors.affiliation: Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
authors.forename: Larysa
authors.initials: L
authors.lastname: Sanchez
authors.affiliation: Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
authors.forename: Yucai
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
authors.forename: David S
authors.initials: DS
authors.lastname: Siegel
authors.affiliation: Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX, 77030, USA. miwang@mdanderson.org.
authors.forename: Michael L
authors.initials: ML
authors.lastname: Wang
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; C556306:daratumumab; D051997:ADP-ribosyl Cyclase 1